论文部分内容阅读
目的制备新型载阿霉素纳米粒子,观察其理化性能,研究其对乳腺癌MDA-MB231细胞凋亡及在裸鼠体内的抑瘤作用,为三阴性乳腺癌的治疗提供依据。方法制备右旋糖苷纳米粒子,构建EGFR-Dextran-DOX纳米材料,Hoechst33258荧光染料及ELISA实验检测MDA-MB231细胞凋亡。将裸鼠随机分为4组,作相应处理后分别注射磷酸缓冲盐溶液(PBS)、阿霉素(DOX)、Dextran-DOX及EGFR-Dextran-DOX,测量各组瘤体大小。结果 EGFR-DextranDOX纳米粒子大小均一,平均粒径98 nm,包封率为77.0%,载药量9.8%。pH值越低,EGFR-Dextran-DOX纳米粒子DOX释放率越高。EGFR-Dextran-DOX处理组的细胞凋亡率及在裸鼠体内的抑瘤作用高于DOX和Dextran-DOX组,差异有统计学意义(P<0.05)。结论成功制备EGFR-Dextran-DOX纳米粒子,制备的纳米粒对三阴性乳腺癌具有靶向抑制作用。
OBJECTIVE To prepare a new type of doxorubicin-containing nanoparticle and observe its physical and chemical properties, and to study its effect on the apoptosis of breast cancer MDA-MB231 cells and its antitumor activity in nude mice and to provide basis for the treatment of triple-negative breast cancer. Methods Dextran nanoparticles were prepared, EGFR-Dextran-DOX nanomaterials were constructed, Hoechst33258 fluorescent dye and ELISA assay were used to detect the apoptosis of MDA-MB231 cells. The nude mice were randomly divided into 4 groups. After corresponding treatment, they were injected with phosphate buffered saline (PBS), doxorubicin (DOX), Dextran-DOX and EGFR-Dextran-DOX respectively. Results The size of EGFR-DextranDOX nanoparticles was uniform, the average particle size was 98 nm, the encapsulation efficiency was 77.0% and the drug loading was 9.8%. The lower the pH, the higher the DOX release rate of EGFR-Dextran-DOX nanoparticles. The apoptosis rate of EGFR-Dextran-DOX group and its antitumor activity in nude mice were higher than those of DOX and Dextran-DOX groups (P <0.05). Conclusion EGFR-Dextran-DOX nanoparticles were successfully prepared and the prepared nanoparticles could inhibit the growth of triple negative breast cancer.